ModiQuest Research and Cellectis to Collaborate
News Mar 07, 2015
ModiQuest Research BV has announced that it has entered into a collaboration with Cellectis aimed at the generation of novel monoclonal antibodies against Cellectis’ target(s).
During the collaboration, ModiQuest may make use of its proprietary electrofusion technology, ModiFuse™. Financial details of the collaboration were not disclosed.
“We are pleased that Cellectis has selected ModiQuest Research as a development partner for its activities,” said Dr. Jos Raats, Managing Director of ModiQuest Research. “This collaboration once more demonstrates the value of our broad and unique antibody generation platform and we are delighted to work together with Cellectis in the emerging field of cancer immunotherapy.”
Macrophage's Role in Maintaining Tattoos Could Hold Key to RemovalNews
Researchers have discovered that, though a tattoo may be forever, the skin cells that carry the tattoo pigment are not. Instead, the cells can pass on the pigment to new cells when they die. The study suggests ways to improve the ability of laser surgery to remove unwanted tattoos.READ MORE
Neuroblastoma Biomarker Research Advances TreatmentNews
Neuroblastoma, a childhood cancer, is treatable in less than half of aggressive cases, but new RNA biomarkers may help identify high-risk patients faster and lead to better prognosis.READ MORE
New Causes of Cellular Decline in Prematurely Aging Kids DiscoveredNews
In a recent paper published in Cell Reports, Saint Louis University researchers have uncovered new answers about why cells rapidly age in children with a rare and fatal disease. The data points to cellular replication stress and a mistaken innate immune response as culprits, and the team found success in the laboratory in blocking these processes with vitamin D.READ MORE
Comments | 0 ADD COMMENT
International Conference on Neuroimmunology, Neurological disorders and Neurogenetics
Sep 26 - Sep 27, 2018